Janssen Vaccines & Prevention B.v.

Taco Gilles Uil

Selina Khan

Jerôme Hubertina Henricus Victor Custers

Koen Oosterhuis

Gerrit Christiaan Scheper

Evelien Margaretha Bunnik

Soumitra Roy

Jort Vellinga

Jerôme H H V Custers

Barbara Petronella Sanders

Kerstin Wunderlich

Remko Van Der Vlugt

John Alfred Lewis

Marija Vujadinovic

Diana Edo-Matas

Jerome H Hv Custers

Jerome H H V Custers

Gerrit Ch Scheper

Evelien M Bunnik

Jerôme HHV Custers

Jerome Hhv Custers

The invention provides an AoHV-1 promoter for use with plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene. The invention also provides methods of making and using recombinant plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene.

Potent and short promoter for expression of heterologous genes

Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.

Adenovirus and uses thereof

Provided herein are adenoviral vectors comprising nucleotide sequences encoding a Zika virus M and Env antigen, wherein the nucleotide sequence encoding the Zika virus M and Env antigen is operably linked to a cytomegalovirus (CMV) promoter comprising at least one tetracycline operator (TetO) motif. Also provided herein are pharmaceutical compositions comprising the adenoviral vectors, methods of producing the adenoviral vectors, methods of preventing Zika virus or the progression of Zika virus in a subject in need thereof, and kits comprising the adenoviral vectors and host cells.

Recombinant adenoviral vector expressing Zika antigen with improved productivity

Provided herein are chimeric adenoviral vectors. The provided chimeric adenoviral vectors can be used to induce a protective immune response in a subject.

Adenovirus vectors and uses thereof

Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV16.

Therapeutic HPV16 vaccines

Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV18 and/or HPV16.

Therapeutic HPV18 vaccines

The present invention relates to novel vaccines against Human papillomavirus (HPV) infections, based on recombinant capsid-display adenovirus vectors. Described are capsid modified replication deficient adenovirus particles encoding and displaying multiple HPV L2 antigenic fragments, via a minor capsid protein IX, and their use for eliciting an immune response in order to provide protection against infections from multiple HPV types.

HPV vaccines

A poliovirus (PV) strain was attenuated by a novel method of Cold-Adapted-Viral-Attenuation (CAVA). The resulting recombinant attenuated PV, CAVA-PV, shows wild-type replication at 30&#xb0; C., but no substantial replication at 37&#xb0; C. The inability to replicate at 37&#xb0; C. is defined by an inability to quantify virus during infection at this temperature by titration (infectious units), qPCR (viral RNA) or Electron Microscopy (visual signs of infection). CAVA-PV is genetically stable under production conditions and shows utility for use as the backbone to produce attenuated strains with the same antigenic profile as conventional vaccines by replacing the sequence coding for the capsid of CAVA-PV with sequences coding for capsids of different PV strains. Furthermore, mutations identified in CAVA-PV can be engineered into different, even wild-type and neurovirulent poliovirus background strains to obtain additional CAVA-PV strains.

Growing community of inventors

Amsterdam, Netherlands

Taco Gilles Uil